ACOG · XBRL financial data

Alpha Cognition financial statements, every quarter

The same tables from 9 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (ACOG's year ends in late December)

In thousands of dollars	Q2 FY24Jun 30, 2024	Q3 FY24†Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Aug 6, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue	—	—	—	2,929	—	2,841	2,793*	3,534	6,093
Cost of revenue	—	—	—	13	—	—	—	—	391
Cost of goods and services sold	—	—	—	—	—	—	year only	—	—
Gross profit	—	—	—	—	—	—	—	—	5,702
Research and development	967	996	1,039*	408	—	574	570*	1,096	2,009
Selling, general and administrative	1,434	1,472	1,632*	5,366	—	6,946	9,891*	10,257	11,449
General and administrative	1,454	1,492	1,502*	—	—	—	—	—	—
Total operating expenses	2,421	2,488	2,540*	6,334	—	—	year only	11,630	13,458
Operating income (loss)	(2,421)	(2,488)	(2,540)*	(3,686)	—	(5,312)	(7,925)*	(8,096)	(7,756)
Interest income	2	2	146*	471	—	—	—	506	381
Interest expense	15	19	63*	9	—	—	—	—	—
Other income (expense)	—	—	—	—	—	—	—	—	42
Net income (loss)	(2,116)	(1,860)	(5,659)*	(2,007)	—	(1,318)	(6,856)*	(6,478)	(8,790)
Earnings per share, basic USD per share	(0.01)	(0.31)	—	(0.13)	—	(0.08)	—	(0.30)	(0.40)
Earnings per share, diluted USD per share	(0.01)	(0.31)	—	(0.13)	—	(0.30)	—	(0.32)	(0.40)
Weighted average shares, basic thousands of shares	150,234	6,030	—	16,020	—	16,144	—	21,762	21,774
Weighted average shares, diluted thousands of shares	150,234	6,030	—	16,020	—	16,144	—	21,926	21,774

† Share count changed about 1/10 in the period ending 2024-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (ACOG's year ends in late December)

In thousands of dollars	Q2 FY24Jun 30, 2024	Q3 FY24†Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Aug 6, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	1,019	3,666	48,546	45,527	—	35,399	66,047	54,248	41,384
Accounts receivable	—	—	—	423	—	2,846	4,236	3,578	5,475
Inventory	—	—	615	883	—	4,499	5,123	6,044	6,395
Prepaid and other current assets	320	741	1,072	1,191	—	2,899	3,545	4,628	4,614
Total current assets	1,514	4,514	50,251	48,119	—	45,702	79,010	68,557	57,927
Property and equipment, net	1	1	27	70	—	203	329	305	375
Total assets	2,082	5,028	50,737	48,608	—	46,301	79,730	69,248	64,520
Accounts payable	484	790	873	822	—	838	3,068	1,435	1,188
Total current liabilities	1,571	3,006	3,351	2,807	—	6,830	9,130	5,425	6,413
Total liabilities	3,475	7,948	9,274	7,797	—	12,387	17,200	11,792	11,558
Accumulated deficit	(68,766)	(70,626)	(76,285)	(78,292)	—	(90,099)	(97,107)	(103,585)	(112,375)
Total stockholders' equity	(1,393)	(2,920)	41,463	40,812	—	33,914	62,530	57,457	52,962
Total liabilities and equity	2,082	5,028	50,737	48,608	—	46,301	79,730	69,248	64,520
Common shares outstanding (cover page) thousands of shares	150,856	15,531	16,020	16,020	16,161	21,742	21,774	21,774	21,778

† Share count changed about 1/10 in the period ending 2024-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (ACOG's year ends in late December)

In thousands of dollars	Q2 FY24Jun 30, 2024	Q3 FY24†Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Aug 6, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(2,116)	(1,860)	(5,659)*	(2,007)	—	(1,318)	(6,856)*	(6,478)	(8,790)
Stock-based compensation	375*	194*	63*	1,355	—	1,458*	946*	1,404	1,452*
Net cash from operating activities	(1,402)*	(1,578)*	(2,304)*	(2,044)	—	(5,290)*	(6,906)*	(11,798)	(6,859)*
Purchases of property and equipment	—	—	year only	63	—	74*	148*	1	99*
Net cash from investing activities	—	—	year only	(63)	—	(74)*	(148)*	(1)	(6,005)*
Proceeds from issuing common stock	0*	0*	0*	—	—	—	—	—	—
Net cash from financing activities	173*	4,157*	47,121*	(834)	—	1,358*	37,702*	1	0*
Net change in cash	—	2,579*	44,791*	—	—	—	—	—	—

† Share count changed about 1/10 in the period ending 2024-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Alpha Cognition	41,384	6,093	(6,859)*	21.8M	6.0 quarters	Q2 FY26 10-QJun 30, 2026
Aclaris Therapeutics	19,167	1,629	(19,847)*	147.2M	4.6 quarters	Q2 FY26 10-QJun 30, 2026
Sangamo Therapeutics	27,586	1,442	(19,282)	414.3M	1.4 quarters	Q1 FY26 10-QMar 31, 2026
Neurogene	112,485	not reported	(23,761)*	20.0M	9.5 quarters	Q2 FY26 10-QJun 30, 2026
Puma Biotechnology	36,537	56,502	1,624*	51.6M	—	Q2 FY26 10-QJun 30, 2026
Eledon Pharmaceuticals	6,803	not reported	(22,677)*	81.3M	3.9 quarters	Q2 FY26 10-QJun 30, 2026
Voyager Therapeutics	35,769	3,165	(25,842)*	61.6M	4.5 quarters	Q2 FY26 10-QJun 30, 2026
Monopar Therapeutics	52,758	0*	(3,247)*	6.7M	32.4 quarters	Q2 FY26 10-QJun 30, 2026
Forte Biosciences	49,629	not reported	(22,702)*	21.2M	8.7 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.